|Bid||0.6001 x 1800|
|Ask||0.6101 x 1800|
|Day's Range||0.5900 - 0.6290|
|52 Week Range||0.4900 - 8.2470|
|Beta (5Y Monthly)||1.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2022 - Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.14|
Ardelyx (ARDX) delivered earnings and revenue surprises of -5% and 87.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. “We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer
Ardelyx (ARDX) delivered earnings and revenue surprises of -24% and 48.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?